抗HBV-DC联合药物治疗e抗原阳性的临床研究(1)
 |
| 第1页 |
参见附件。
[摘要]目的 观察HBsAg致敏自体外周血单个核细胞(PBMC)来源的树突状细胞联合拉米夫定和胸腺肽α1治疗HBeAg阳性慢乙肝的临床效果。 方法 HBeAg阳性CHB患者20例接受临床研究。取肝素抗凝外周静脉血50mL，以密度梯度离心及贴壁法获得PBMC，GM-CSF和IL-4诱导扩增DC，第6天给予30 μg的HBsAg致敏DC，第7天收获抗HBV-DC。联合拉米夫定和胸腺肽α1，分别于0、4、12周检测HBVM定量和HBV-DNA定量及肝功能。 结果 全部患者治疗后4、12周的HBsAg、HBeAg和HBV-DNA均明显下降。总有效率100%(20/20)。 结论 抗HBV-DC联合拉米夫定和胸腺肽α1治疗，可快速降低血中HBsAg、HBeAg和HBV-DNA，促进HBeAb的产生，提高HBeAg/HBeAb的血清学转换率。
[关键词] 树突状细胞；慢性乙型肝炎；乙肝疫苗
[中图分类号] R512.62 [文献标识码] B [文章编号] 1673-9701(2012)01-077-03
Preliminary clinical study of anti-HBV-DC combine lamivudine and thymosin α1 treat the HBeAg positive chronic hepatitis B patients
LIU Yong WU Bangfu HU Yuanyuan
Gastroenterology and Hepatology Center, Southern Medical University Renkang Hospital, Dongguan 523952, China
[Abstract] Objective To observe the clinical treatment effects of the HBsAg pulsed autologous dendritic cells derived from peripheral blood mononuclear cells (PBMC) combine lamivudine and Thymosin-α1 for the HBeAg positive chronic hepatitis B patients. Methods Twenty patients with HBeAg positive CHB accepted by clinical research. Taking peripheral venous blood 50mL, by density gradient centrifugation and adhesion method to obtain PBMC, GM-CSF and IL-4 induced expansion of DC. At the sixth days, a 30 μg HBsAg was give to pulse the DC. At the seventh days, the anti-HBV-DCs. All patients were Lamivudine dosed every day, and were injected thymosin-α1 by subcutaneous, The HBVM, HBV-DNA and liver function were respectively detected at 0,4,12 weeks. Results At 0,4,12 weeks, the serum HBsAg levels, the serum HBeAg levels and the serum HBV-DNA levels were significantly decreased. The total effective rate was 100% (20/20). Conclusion The anti-HBV-DC by subcutaneous and intravenous injection combine lamivudine and Thymosin-α1 can decrease rapid the serum HBsAg, HBeAg and HBV-DNA levels, promote to the HBeAb production, and enhance the HBeAg/HBeAb seroconversion rate.
[Key words] Pulsed autologous dendritic cells; HBsAg; Hepatitis B vaccine
机体免疫系统对HBV产生免疫耐受是人感染HBV后慢性化的主要原因。形成免疫耐受的原因可能有多种因素参与 ......
您现在查看是摘要介绍页，详见PDF附件(2777kb)。